These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1536 related articles for article (PubMed ID: 17960013)
1. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. Posner MR; Hershock DM; Blajman CR; Mickiewicz E; Winquist E; Gorbounova V; Tjulandin S; Shin DM; Cullen K; Ervin TJ; Murphy BA; Raez LE; Cohen RB; Spaulding M; Tishler RB; Roth B; Viroglio Rdel C; Venkatesan V; Romanov I; Agarwala S; Harter KW; Dugan M; Cmelak A; Markoe AM; Read PW; Steinbrenner L; Colevas AD; Norris CM; Haddad RI; N Engl J Med; 2007 Oct; 357(17):1705-15. PubMed ID: 17960013 [TBL] [Abstract][Full Text] [Related]
2. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL; N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166 [TBL] [Abstract][Full Text] [Related]
4. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future? Paccagnella A; Mastromauro C; D'Amanzo P; Ghi MG Oncologist; 2010; 15 Suppl 3():8-12. PubMed ID: 21036883 [TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR; Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014 [TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up. Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant docetaxel, cisplatin and 5-fluorouracil (TPF) in locally advanced squamous cell carcinoma of the head and neck. Baghi M; Hambek M; May A; Radeloff A; Gstoettner W; Knecht R Anticancer Res; 2006; 26(1B):559-63. PubMed ID: 16739320 [TBL] [Abstract][Full Text] [Related]
9. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas. Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580 [TBL] [Abstract][Full Text] [Related]
10. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415 [TBL] [Abstract][Full Text] [Related]
11. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma. Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854 [TBL] [Abstract][Full Text] [Related]
12. Relationship between radiation treatment time and overall survival after induction chemotherapy for locally advanced head-and-neck carcinoma: a subset analysis of TAX 324. Sher DJ; Posner MR; Tishler RB; Sarlis NJ; Haddad RI; Holupka EJ; Devlin PM Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e813-8. PubMed ID: 21300455 [TBL] [Abstract][Full Text] [Related]
13. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial. Cullen KJ; Schumaker L; Nikitakis N; Goloubeva O; Tan M; Sarlis NJ; Haddad RI; Posner MR J Clin Oncol; 2009 Dec; 27(36):6222-8. PubMed ID: 19917838 [TBL] [Abstract][Full Text] [Related]
14. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma. Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506 [TBL] [Abstract][Full Text] [Related]
15. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Institute experience. Haddad R; Colevas AD; Tishler R; Busse P; Goguen L; Sullivan C; Norris CM; Lake-Willcutt B; Case MA; Costello R; Posner M Cancer; 2003 Jan; 97(2):412-8. PubMed ID: 12518365 [TBL] [Abstract][Full Text] [Related]
16. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck. Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810 [TBL] [Abstract][Full Text] [Related]
17. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256 [TBL] [Abstract][Full Text] [Related]
18. Comparison of hyperfractionation and conventional fractionation radiotherapy with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). Katori H; Tsukuda M; Watai K Cancer Chemother Pharmacol; 2007 Aug; 60(3):399-406. PubMed ID: 17096160 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients. Fayette J; Bonnin N; Ferlay C; Lallemant B; Ramade A; Favrel V; Zrounba P; Chabaud S; Pommier P; Poupart M; Céruse P Anticancer Drugs; 2013 Jul; 24(6):623-9. PubMed ID: 23542750 [TBL] [Abstract][Full Text] [Related]
20. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck. Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ; Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]